SEC Form 3 · accession 0000905148-26-004064
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michaela Levin
Officer — Chief Business Officer
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001781174
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
No Table II lines on this filing.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney